AstraZeneca and Daiichi Sankyo presented Phase 3 data at ESMO showing Enhertu improves outcomes when used earlier in breast cancer treatment. The companies reported results indicating meaningful benefit in pre‑surgical and early-stage settings, prompting discussion about moving the antibody‑drug conjugate (ADC) into potentially curative use. ADCs are targeted therapies that link a monoclonal antibody to a cytotoxic payload to deliver chemotherapy directly to tumor cells. Presentations at the European Society for Medical Oncology (ESMO) included trial details on response rates and timing of administration; investigators highlighted implications for expanding patient populations eligible for Enhertu. Regulators and oncology centers will need to weigh efficacy data against safety profiles as sponsors prepare potential label expansions and new regulatory filings. Clinical teams noted the shift of ADCs from late‑line to earlier disease stages, with potential impact on surgical planning and adjuvant therapy approaches.